ライフサイエンスコーパス: mortality

1 d invasive tumors with high disease-specific mortality.

2 tubation, ICU length of stay, and short-term mortality.

3 e common and contribute to organ failure and mortality.

4 er when pathogens acted as codrivers of tree mortality.

5 ED-LOS, HLOS, complications, and in-hospital mortality.

6 hat induced significant short- and long-term mortality.

7 ignificant variation was found for perinatal mortality.

8 cirrhosis with equivalence to LB in terms of mortality.

9 a lower risk of all-cause and cardiovascular mortality.

10 itation, plant compositional shifts and tree mortality.

11 ansmission lines, are substantial sources of mortality.

12 and the secondary outcome was cause-specific mortality.

13 Crs was independently associated with higher mortality.

14 tive defense strategy against viral-mediated mortality.

15 he PBS was not independently associated with mortality.

16 raft failure cause significant morbidity and mortality.

17 ns that most cost-effectively reduce PM(2.5) mortality.

18 k for a first hepatic decompensation and for mortality.

19 E hospitalizations, and 36% (IQR, 28-46) AGE mortality.

20 may be transient due to lagged increases in mortality.

21 y is associated with increased morbidity and mortality.

22 n expression, bacterial burden, and neonatal mortality.

23 cal care that directly affects morbidity and mortality.

24 ause a vast majority of cancer morbidity and mortality.

25 risk factor for cardiovascular morbidity and mortality.

26 extracutaneous manifestations, morbidity and mortality.

27 serious bleeding and increased morbidity and mortality.

28 OVID-19 to help predict disease severity and mortality.

29 is associated with substantial morbidity and mortality.

30 risk-adjusted predictors of post-transplant mortality.

31 , five for increased intervention-associated mortality.

32 a cytokine storm may increase morbidity and mortality.

33 is associated with substantial morbidity and mortality.

34 AVR, TAVR utilization rates, and in-hospital mortality.

35 ensity of stepping are associated with lower mortality.

36 ctors and phenotypes and between factors and mortality.

37 be vulnerable to COVID-related morbidity and mortality.

38 d to examine the association of ECLS use and mortality.

39 The primary endpoint was all-cause mortality.

40 were cardiovascular disease (CVD) and cancer mortality.

41 ibute substantially to overall morbidity and mortality.

42 personalized treatment regimens could reduce mortality.

43 diagnosis is an important cause of its high mortality.

44 th renal function decline and cardiovascular mortality.

45 management, respiratory failure, and patient mortality.

46 antioxidants was seen with CVD and all-cause mortality.

47 en the number of risk factors and subsequent mortality.

48 There was no toxic mortality.

49 rder to curb iatrogenic opioid morbidity and mortality.

50 e proportion of the population, causing high mortality.

51 cumulation of chronic diseases and all-cause mortality.

52 on associated with significant morbidity and mortality.

53 ted with increased vascular permeability and mortality.

54 erence between groups, including in-hospital mortality (1.7% for uncemented fixation vs 2.0% for ceme

55 for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoid

56 day readmission (-9.8%, P=0.0002) and 30-day mortality (-2.6%, P=0.041).

57 Care Act uninsured patients had the highest mortality (25.68%).

58 Hospital mortality (29.75% vs 21.1%), combined mortality, or disc

59 ; 95% CI, -0.1 to 0.2; P = .58) or in 30-day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1

60 inant, endemic(6-8) and associated with high mortality(6,9,10).

61 le (ie, highest mortality) of fully adjusted mortality, 60% were located in 3 states: Oklahoma, Texas

62 rval: 0.68 to 0.88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjusted hazard ratio: 0.61; 9

63 h COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with

64 r coronary heart disease, CVD, and all-cause mortality according to categories of BMI and CAC.

65 strated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/umeclidini

66 omes did not show significant differences in mortality across teaching and nonteaching environments,

67 KI-RRT patients had lower rates of long-term mortality (adjusted hazard ratio (HR), 0.473; 95% CI, 0.

68 ype interaction predicting time to all-cause mortality, adjusted for Meta-Analysis Global Group in Ch

69 nts with T2MI had higher long-term all-cause mortality after adjustment for age and sex, driven by ea

70 remains an important cause of morbidity and mortality after allogeneic hematopoietic cell transplant

71 aimed to report postoperative morbidity and mortality after esophagectomy and gastrectomy in the Net

72 a chemoprevention could reduce morbidity and mortality after hospital discharge in children younger t

73 %) were the most robust predictors of 1-year mortality after incident and repeated HFHs, respectively

74 lure (RVF) is a cause of major morbidity and mortality after left ventricular assist device (LVAD) im

75 Mortality after TAI was 7.8%, and depended on injury sev

76 ed hazard ratio (aHR) for MACCE or all-cause mortality (aHR, 1.71 [1.13-2.60]; P = 0.012) even after

77 mplications, and higher short- and long-term mortality (all P < 0.05).

78 no device, was associated with lower risk of mortality, all-cause hospital admission, and intubation,

79 We studied 30-day mortality among 1,483,074 Medicare beneficiaries undergo

80 n, and more intensive antifungals may reduce mortality among asymptomatic CrAg-positive patients iden

81 a worthwhile strategy for preventing CVD and mortality among older Mexican Americans with insufficien

82 conditions and all-cause and cause-specific mortality among survivors of early-adolescent and young

83 and stroke, are the leading cause of global mortality and a major contributor to disability.

84 U survivor care process results in decreased mortality and a net annual cost savings to the insurer c

85 od concentrations are associated with higher mortality and a poorer physiological state, and (3) C15:

86 RBC transfusion correlates with increased mortality and acute kidney injury early after transcathe

87 in critically ill patients do not influence mortality and are safe.

88 fections are common and substantially impact mortality and DCGF, even in the modern era.

89 Ratios for mortality and graft loss were similar between VA centers

90 was conducted to describe the trajectory of mortality and health-related quality of life morbidity f

91 class on presentation, and the end points of mortality and heart failure admissions in the CASTLE-AF

92 Mortality and mobility were assessed at 30 and 60 d afte

93 nakebite is a medical emergency causing high mortality and morbidity in rural tropical communities th

94 acterial neonatal meningitis results in high mortality and morbidity rates for those affected.

95 Coronary artery disease (CAD) causes mortality and morbidity worldwide.

96 r surgery associated with increased risk for mortality and morbidity.

97 long-term survival, postoperative morbidity, mortality and pathology results.

98 uptake, a primary determinant of prognosis, mortality and quality of life, is diminished in patients

99 en were limited to prevented cases of infant mortality and respiratory illnesses, with a monetized im

100 between handgun ownership and both all-cause mortality and suicide (by firearm and by other methods)

101 cluding a group closest to HFrEF with higher mortality, and a mostly female group with smaller hearts

102 We characterized clinical parameters, mortality, and B cell phenotypes in blood and cerebrospi

103 e pregnancy outcomes, maternal TB, all-cause mortality, and liver injury during pregnancy through 12

104 on observed waitlist registrations, waitlist mortality, and living-donor and deceased-donor kidney tr

105 ate, intensive care unit mortality, hospital mortality, and physical function- and mental health-rela

106 ciation between BCG vaccination and COVID-19 mortality, and suggest that BCG could have a protective

107 The primary outcome was all-cause mortality, and the secondary outcome was cause-specific

108 -90 treatment targets on HIV-1 incidence and mortality, and to assess whether these interventions wil

109 link between regular yogurt consumption and mortality appears plausible, data are sparse and have yi

110 ment in a state with a high rate of dialysis mortality are at a higher risk for transplant failure co

111 Colorectal cancer (CRC) incidence and mortality are increasing among persons younger than 50 y

112 ry disease was not associated with increased mortality, as has been suggested for peripheral arteries

113 the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective

114 flated) estimate for the average increase in mortality associated with each hour until antibiotics, a

115 cose metabolism disorders are susceptible to mortality associated with fine particles.

116 In this study, we quantified excess mortality associated with mental disorders in HIV-positi

117 We examined characteristics and mortality associated with rifampin-monoresistant (RMR) T

118 male sex was not an independent predictor of mortality at 10 years in patients with complex coronary

119 pothermia was associated with an increase in mortality at longest follow-up available (432/1,375 [31%

120 untries with large annual reductions in such mortality between 1990 and 2017 had achieved low levels

121 true magnitude of difference in HIV-related mortality between men and women receiving antiretroviral

122 nin-guided therapy trials have shown similar mortality, but the essential question is whether the sen

123 adiposity are independently associated with mortality, but there is no consensus on how best to asse

124 p<0.001) with a relative decrease in 30-day mortality by -1.6% (95% CI, -3.4 to -0.2, p = 0.039) and

125 (95% CI, -3.4 to -0.2, p = 0.039) and 90-day mortality by -2.3% (95% CI, -4.3 to -0.4, p = 0.018).

126 0, scaling up vaccination alone would reduce mortality by 61.7% (61.4-66.1), averting 4.8 million (4.

127 Letermovir may reduce mortality by preventing or delaying CS-CMVi in HCT recip

128 The decreases in deaths attributed to mortality change from 1990 to 2017 were more than the in

129 0 g/day yielded increased risk estimates for mortality compared to lifetime abstainers.

130 ar rates of HF hospitalization and all-cause mortality compared with GDMT alone.

131 We examined clinical safety outcomes (mortality, complications, and reinterventions), healthca

132 Here, we show that tree mortality concomitant with drought has led to short-term

133 As HIV incidence and mortality continue to increase in eastern Europe and cen

134 Here we directly set national PM(2.5) mortality cost reduction targets within a global human-e

135 ren aged 12-23 months was 84% (79-89) in low-mortality countries.

136 94 [95% CI, 0.73-1.21]; P = .61) and overall mortality (cumulative incidence at 1 year after operatio

137 From the dose-response curves of mortality data created as a function of various beam dia

138 Risk-adjusted mortality declined with increasing discharge delay and w

139 Although all-cause mortality decreased 16.4% across all ages, mortality res

140 000-2003 and 2012-2015, the adjusted overall mortality decreased by 24% (hazard ratio [HR] per year 0

141 driver, female pups exhibit no morbidity or mortality despite partial X reactivation.

142 Meta-regression of the effect of dose on mortality did not reveal an association, but reported do

143 For chronic limb-threatening ischemia, the mortality difference was not significant; paclitaxel (12

144 cally, tracheostomy complications, inpatient mortality, disposition of patients, and transmission of

145 rrence-free survival (RFS), disease-specific mortality (DSM), and time-to-recurrence, were reported.

146 n their vulnerability to different causes of mortality due to traits, life history stages, or locatio

147 nic inflammation and increased morbidity and mortality during antiretroviral-treated HIV disease.

148 tokine responses that are protective against mortality during experimental sepsis.

149 pendency at 30 days and 1 year and all-cause mortality during follow-up were evaluated.

150 tients with septic shock), blending together mortality estimates from patients with very long interva

151 Recent unionid mass mortality events around the world threaten ecosystem ser

152 arteries is implicated in events leading to mortality following MI.

153 We also investigated the mortality for all patients with HF and in COVID-19-infec

154 cess in composite 30-day HF readmissions and mortality for Black patients ranged from 3.9% (95% CI, 1

155 relationship between time-to-antibiotics and mortality for patients with possible sepsis is therefore

156 from 2006 to 2017 with 30-day post-discharge mortality from 5.1% to 4.4%.

157 Mortality from coronavirus disease 2019 (COVID-19) is st

158 d achieved low levels of premature avertable mortality from NCDs by 2017.

159 In contrast, mortality from SCLC declined almost entirely as a result

160 h presumptive COVID-19 and low likelihood of mortality from STEMI and use of preventive strategies su

161 r profile, the absolute age-standardized CVD mortality gap would decline by 33.3% (95% CI 25.1-40.1)

162 cardiovascular disease is the major cause of mortality globally.

163 tries, reductions in stillbirth and neonatal mortality have been slow.

164 The mortality hazard ratio was high at 6.01 (95% CI, 4.02-10

165 agrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92])

166 was significantly associated with all-cause mortality (hazard ratio [HR], 1.49 [CI, 1.15 to 1.94]) a

167 te of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95% CI, 0.80-1.06])

168 strength, delirium rate, intensive care unit mortality, hospital mortality, and physical function- an

169 HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there

170 1.49 [CI, 1.15 to 1.94]) and cardiovascular mortality (HR, 1.66 [CI, 1.07 to 2.57]) in participants

171 nts' MELD) was associated with postoperative mortality (HR: 8.027; 95% CI: 2.387-18.223; P = 0.026) a

172 aminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general

173 growth, blood-brain barrier dysfunction, and mortality in a mouse model of malaria.

174 utbreaks result in significant morbidity and mortality in affected countries.

175 reater absolute rate differences in neonatal mortality in all gestational-age strata.

176 excess in combined 30-day HF readmissions or mortality in any of the neighborhood quartiles.

177 The FLIS was an independent risk factor for mortality in both patients with CACLD (adjusted hazard r

178 We estimated 1-year mortality in each condition, developing simple models (a

179 ubstantial reductions in HIV-1 incidence and mortality in eSwatini.

180 that is a major cause of diarrhea-associated mortality in humans.

181 Short-term mortality in ICU-admitted stroke patients was high with

182 d determine the risk factors of transfer and mortality in IHT patients.

183 RS were moderately associated with all-cause mortality in independent data within the UK Biobank: the

184 ts to improving post-discharge morbidity and mortality in LMICs.

185 IPA) is a significant cause of morbidity and mortality in lung transplant recipients (LTRs).

186 Among 20 studies of patient mortality in nonobstetrical care settings, 15 found no e

187 infusion decreases the incidence of PICD and mortality in patients with ACLF.

188 Fluid overload was associated with mortality in patients with both acute kidney injury (adj

189 D) and LA at admission may predict inpatient mortality in patients with CLD.

190 emia ratio was significantly associated with mortality in patients with glycosylated hemoglobin less

191 specific multimorbidity patterns may reduce mortality in patients with multimorbidity.

192 tation aimed at closing the CO2 gap improves mortality in shock.

193 Results were also null for cardiovascular mortality in the 2 external cohorts (eg, HRs of IDH by t

194 risk factors predisposing to severe disease/mortality in the general population also seemed to affec

195 s one of the leading causes of morbidity and mortality in the globe.

196 HCC as a cause of morbidity and mortality in the HBV/HIV co-infected patient population.

197 -19) pandemic has led to a large increase in mortality in the United States and around the world, lea

198 ve alcohol use is the third leading cause of mortality in the United States, where alcohol use consis

199 ominate the process during the end stages of mortality in these conifers.

200 on tension was independently associated with mortality in this cohort of venoarterial extracorporeal

201 h estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or

202 20 combinations most highly associated with mortality in UK Biobank and 12 of the top combinations i

203 est the implications of parasites for annual mortality in wild bird populations using phylogenetic co

204 tree was constructed with associated 2-year mortality incorporating an LB or NIT strategy to diagnos

205 periencing a complication, as well as 30-day mortality, independent of other hospital level character

206 nt and is an independent predictor of 30-day mortality, irrespective of periprocedural major bleeding

207 th acute kidney injury (AKI) and the risk of mortality is high, especially if renal replacement thera

208 ng TPVR in the C3PO-QI registry is high, but mortality is uncommon.

209 d sex and the composite outcome of all-cause mortality, LV assist device implantation, or heart trans

210 mplications in determining urgency of LT and mortality models in cirrhosis and LT waitlisting, especi

211 pose that to understand causes of sex-biased mortalities, more complex analyses are needed that incor

212 Outcomes were in-hospital mortality, mortality rates based on insurance type, and

213 Mortality occurred in 6.0% of infants in the DHA group v

214 r Simplified Acute Physiology Score II, with mortality (odds ratio, 2.31; 1.83-2.92).

215 mitted stroke patients was high with 30 days mortality of 31% in ischemic stroke and 42% in intracere

216 -based estimate of on-board and post-release mortality of bycaught marine turtles that has until now

217 timated harvest and background (other cause) mortality of landlocked migratory salmonids over half a

218 ures to classify target diseases and predict mortality of patients in critical conditions.

219 The mortality of post-HCT AIC reduced from 25% (4 of 16) pri

220 SAP2 silencing fully restores mortality of the mosquitoes, whereas SAP2 overexpression

221 Due to late diagnosis of this disease, the mortality of this condition is very high.

222 COVID-19 pandemic (compared with background mortality) of 1.5, 2.0, and 3.0 at differing infection r

223 ies in the top fifth percentile (ie, highest mortality) of fully adjusted mortality, 60% were located

224 ionally, we analyzed the effects of drought- mortality on second-entry burn emissions and compared em

225 Clinical characteristics, MELD-Na, and mortality on the waiting list were recorded.

226 sis among patients with hypertension or with mortality or severe disease among patients diagnosed as

227 67 was also associated with increased 30-day mortality (OR, 8.4 [95% confidence interval, 2.23-31.7])

228 spital mortality (29.75% vs 21.1%), combined mortality, or discharge to hospice (37.2% vs 25.3%), ext

229 sociated with significant decrease in day 30 mortality over time (odds ratio, 0.96; 95% CI, 0.93-0.98

230 tion)<0.0001; 1.9% versus 0.6% for all-cause mortality, P(interaction)=0.02; 2.7% versus 1.7% for maj

231 he magnitude of sex differences in mammalian mortality patterns is likely shaped by local environment

232 an accurate prediction for almost all 30-day mortality probabilities.

233 overall survival, with a 2-fold decrease in mortality rate (HR, 0.50; 95% CI, 0.27 to 0.90), were ob

234 The mortality rate among the 835 participants who had initia

235 Mortality rate was 22.3% (n = 25); 72.3% (n = 81) were h

236 Consistent with late presentations, the mortality rate was high, whereas frequencies of LVRR and

237 t dialysis treatment in a state with a lower mortality rate.

238 quiring two treatments (ii) complication and mortality rates (iii) local and distant recurrence (LR),

239 64 days), child (age 1-4 years), and under-5 mortality rates (U5MRs) for each ethnic group within eac

240 All AMI risk-adjusted mortality rates also declined from 2006 to 2017 with 30-

241 Annual mortality rates among breast cancer patients were signif

242 Outcomes were in-hospital mortality, mortality rates based on insurance type, and hospital le

243 g-computation was used to estimate adjusted mortality rates by sex and age.

244 The higher mortality rates in people with severe mental illness (SM

245 ed the largest reduction in particle-related mortality rates respectively.

246 Adjusted state-specific hemodialysis mortality rates were determined in 3-year intervals amon

247 ure risk may be driving higher infection and mortality rates.

248 community-acquired pneumonia leading to high mortality rates.

249 Disease Surveillance Point system and local mortality records.

250 ereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.

251 ion as this holds the greatest advantage for mortality reduction.

252 D-19 pandemic and to closely examine the Crs-mortality relationship.Methods: We undertook a secondary

253 ore per nurse ratio on day 1 and in-hospital mortality remained significant (odds ratios, 1.29 and 1.

254 Mortality remains high, but the majority of patients wer

255 e interval, 0.47-1.01) for 28-day and 90-day mortality, respectively.

256 e mortality decreased 16.4% across all ages, mortality resulting from CHD declined 39.4% overall.

257 ]: 2.493.494.89, P < 0.001), but a 62% lower mortality risk (aHR: 0.310.380.46, P < 0.001) beyond thi

258 The gradual alteration of mortality risk after ICU admission was assessed using le

259 Higher nut intake was associated with lower mortality risk from both cardiovascular and noncardiovas

260 stic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never

261 ion models were used to assess predictors of mortality risk in these patients.

262 Taking excess mortality risk into consideration, this reduction in the

263 ed with expected population survival, excess mortality risks of pure AR, AR + OMR, and AR + FMR were

264 For stable CAD, PCI did not reduce mortality (RR, 0.98 [95% CI, 0.87-1.11]), cardiac death

265 surgical aortic valve replacement (SAVR) for mortality, stroke, and rehospitalization.

266 days after symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95%

267 jury remains a major driver of morbidity and mortality, the ability to accurately identify patients a

268 an established risk factor for morbidity and mortality, the minimum amount of weight loss to have a m

269 xamined during 1971 to 1991 and followed for mortality through 1992.

270 d and stable reductions in CRC incidence and mortality throughout the entire follow-up.

271 hese parasites can cause major pathology and mortality to livestock leading to significant welfare an

272 llapsibility were independent predictors for mortality, together with base excess and Glasgow Coma Sc

273 fered among family lineages, and the highest mortality under OA occurred in the fastest growing cross

274 nal observational study of COVID-19 hospital mortality using data from the SIVEP-Gripe (Sistema de In

275 short-term (mean 5 y, range 1 to 23 y after mortality) vegetation-type conversion in multiple biomes

276 timately, C starvation may lead to increased mortality vulnerability, but hydraulic failure or biotic

277 aseline variables, the odds ratio for 90-day mortality was 0.82 (95% CI, 0.68 to 0.98).

278 obactam for both endpoints: day 28 all-cause mortality was 15.9% with imipenem/cilastatin/relebactam

279 Three-month mortality was higher in group A than in group B (17.8% a

280 Over a median follow-up of 10.2 years, mortality was highest for myocardial injury (45.6%), fol

281 In the subgroup analysis, in-hospital mortality was lower in patients operated in centers with

282 t quintiles were compared; however, neonatal mortality was significantly associated with SO2 (1.207 [

283 of follow-up (n = 1,775, 9 RCTs), all-cause mortality was significantly lower in the DCB group when

284 Mortality was similar before and after the national lock

285 The primary outcome, in-hospital mortality, was analyzed using a multivariable logistic r

286 mission sector contribution to PM2.5-related mortality, we found that reductions in sulfur-dioxide em

287 In-hospital, 30-day, and 90-day mortality were 3.2%, 3.6%, and 4.5%, respectively.

288 Postoperative morbidity and mortality were 38% and 2%, respectively.

289 stay (HLOS); complications; and in-hospital mortality were compared before (PRE) and after (POST)imp

290 tive incidence of oncologic and nononcologic mortality were compared using competing risks approaches

291 I 1 year and beyond, the effects on MACE and mortality were consistent irrespective of time since las

292 All-cause and cardiopulmonary mortality were identified through linkage to China's Dis

293 Factors significantly associated with 90-day mortality were: P: age, gender and ACLF type; I: drug, i

294 1) were independently associated with day 30 mortality, whereas underlying malignancy, allogeneic hem

295 ciated with AMI incidence and cardiovascular mortality with all four methods.

296 0.93]) had the best predictive value for ICU mortality with cutoff values less than or equal to 1.25

297 pendymal lining, marked meningitis, and 100% mortality within 2 weeks postinfection.

298 , 0.96-0.97) lower adjusted critical illness mortality within a non-minority-serving hospital, but no

299 ic ethanol consumption is a leading cause of mortality worldwide, with higher risks to develop pulmon

300 ease (CAD) is a major cause of morbidity and mortality worldwide.

301 le (i.e. high bacillary load) had 57% 2-week mortality; worse than the intermediate (17%) and high (2